Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
20 authors.
Deepti AgrawalMedical Department III, School of Medicine, Technical University of Munich, Munich, Germany.ORCID 0000-0002-9541-1704
Katarina CisarovaDivision of Oncology, Medical University of Graz, Graz, Austria.ORCID 0000-0003-2711-0480
Sebastian VosbergDivision of Oncology, Medical University of Graz, Graz, Austria.ORCID 0000-0002-8464-1483
Fabian AllmendingerDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.ORCID 0000-0002-5826-7707
Enkhtsetseg MunkhbaatarMedical Department III, School of Medicine, Technical University of Munich, Munich, Germany.
Nadia DandachiDivision of Oncology, Medical University of Graz, Graz, Austria.ORCID 0000-0001-9093-0743
Francisco Jose Fernandez HernandezDivision of Oncology, Medical University of Graz, Graz, Austria.
Marta ToniettoDivision of Oncology, Medical University of Graz, Graz, Austria.
Vanessa JägerDivision of Oncology, Medical University of Graz, Graz, Austria.ORCID 0009-0003-7761-3606
Martina AntonInstitute of Molecular Immunology, School of Medicine, Technical University of Munich, University Hospital rechts der Isar, Munich, Germany.ORCID 0000-0001-5290-5213
Eva C KellerMedical Department III, School of Medicine, Technical University of Munich, Munich, Germany.ORCID 0000-0001-6146-9425
Moritz JesinghausInstitute of Molecular Immunology, School of Medicine, Technical University of Munich, University Hospital rechts der Isar, Munich, Germany.
Anna-Lena MeinhardtMedical Department III, School of Medicine, Technical University of Munich, Munich, Germany.
Verena HaefnerInstitute of Lung Health and Immunity (LHI), Comprehensive Pneumology Center, Helmholtz Munich, Member of the German Center for Lung Research, Munich, Germany.
Tobias StoegerInstitute of Lung Health and Immunity (LHI), Comprehensive Pneumology Center, Helmholtz Munich, Member of the German Center for Lung Research, Munich, Germany.ORCID 0000-0002-2790-0389
Katja SteigerInstitute of Molecular Immunology, School of Medicine, Technical University of Munich, University Hospital rechts der Isar, Munich, Germany.ORCID 0000-0002-7269-5433
Nicholas McGranahanCancer Research UK Lung Cancer Center of Excellence, University College London Cancer Institute, Paul O'Gorman Building, London WC1E 6BT, UK.ORCID 0000-0001-9537-4045
Michael A DenglerDivision of Oncology, Medical University of Graz, Graz, Austria.ORCID 0000-0002-1693-1761
Adam WahidaMedical Department III, School of Medicine, Technical University of Munich, Munich, Germany.ORCID 0000-0002-8856-8834
Philipp J JostMedical Department III, School of Medicine, Technical University of Munich, Munich, Germany.ORCID 0000-0003-2454-0362
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Evasion of programmed cell death is a critical hallmark of cancer. However, the contribution of inflammatory forms of cell death in lung carcinogenesis and their effects on the composition of the tumor-immune microenvironment remain unclear. Our multi-omics analyses of samples from patients with primary lung adenocarcinoma revealed that necrosome signaling is repressed because of reduced expression of receptor-interacting protein kinase 3 (
Indexed as
Adenocarcinoma of LungDNA MethylationGene Expression Regulation, NeoplasticInflammationLung NeoplasmsReceptor-Interacting Protein Serine-Threonine KinasesAnimalsCell Line, TumorFemaleHumansMicePromoter Regions, GeneticSignal TransductionTumor MicroenvironmentReceptor-Interacting Protein Serine-Threonine KinasesRIPK3 protein, human
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Aberrant methylation limits antitumoral inflammation in lung adenocarcinoma by restricting RIPK3 expression. · full record | OpenQuestion